Linagliptin

Hypoglycaemic excluding Insulin · Dipeptidyl peptidase-4 inhibitor

Indications

Type II diabetes inadequately controlled by diet and exercise: as monotherapy when metformin alone is inadequate; with metformin when metformin alone is inadequate, with metformin and a sulfonylurea when dual therapy is inadequate; or with insulin when insulin with or without metformin, is inadequate.

Dosage

Adults: 5 mg daily. In combination therapy consider lower dose of sulfonylurea or insulin. Children: Not recommended.

Adverse Effects

Hypoglycaemia.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Contraindications: Diabetic ketoacidosis. Precautions: Risk of pancreatitis; advise patient of symptoms, discontinue if suspected. Elderly > 80 years.

Interactions

Potent CYP3A4 and P-gp inducers.

Advice to Patient

Take with or without meals.

Pharmacokinetics

Metabolism: Via minor elimination pathway. A small fraction is converted into an inactive metabolite. Bioavailability: Approx 30%. Time to peak, plasma: 1.5 hrs. Excretion: Faeces (80%). Urine (5%).

Brands with this active ingredient

• Celampa-L
• Diajard forte XR
• Diajard L
• Diampa L XR
• Diampa LT
• Diblay-L
• Elm XR
• Elzaflo-LG
• Elzanor-TXR
• Emfera-L
• Emglif-L
• Emglif-LM
• Emjard-L
• Emjard-LM
• Empaa-L

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.